Skip to main content
Figure 3 | BMC Health Services Research

Figure 3

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Figure 3

Per-patient-per-month health care costs for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients. Note: All differences between the two cohorts were significant at P <0.001, with the exception of Pharmacy which was P = 0.082. Statistical significance was tested using the nonparametric Wilcoxon test.

Back to article page
\